Deferiprone (GPO-L-ONE®) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand

• Main Authors: Viprakasit V., Nuchprayoon I., Chuansumrit A., Torcharus K., Pongtanakul B., Laothamatas J., Srichairatanakool S., Pooliam J., Supajitkasem S., Suriyaphol P., Tanphaichitr V.S., Tuchinda S.
• Format: Article
• Language: English
• Published: 2014
• Online Access: http://www.scopus.com/inward/record.url?eid=2-s2.0-84875619524&partnerID=40&md5=5e16ac980c779127d7b23c4a0e1095c6; http://cmuir.cmu.ac.th/handle/6653943832/4175
• Institution: Chiang Mai University

Accessibility to iron chelators including deferoxamine and deferasirox remains obscured in many developing countries. To provide an alternative, the government pharmaceutical organization of Thailand (GPO) manufactured deferiprone which has similar bioequivalent to the standard product. Seventy-thre...